European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

The adalimumab segment is the largest revenue contributor to the market. Based on indication, the global biosimilar monoclonal antibodies market is segmented into oncology, autoimmune diseases ...

Crucially, Humira costs the NHS more than £500 million a year, a sum that NHS England wants to see fall through biosimilar use. Sandoz is one such company that hopes to offer the NHS savings ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to ... Program together with adalimumab-aaty will help us ...

If you're looking for safety within the healthcare sector, a top name to consider right now is Abbott Laboratories. For ...

As a part of this transaction, we are also acquiring a new preclinical development program, a biosimilar candidate to Cimzia that is in the same category of biologics as Humira and Stelara.

The biosimilar will launch in the United States in June 2025 as part of a global settlement with Amgen, which manufactures the reference product. The higher dosage of denosumab-bnht (Bomyntra ...

HERCESSI in the U.S., Zercepac in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab ...

March 29 (UPI) --Rapper Playboi Carti's I Am Music is the No. 1 album in the United States this week. Coming in at No. 2 on the Billboard 200 chart dated Saturday is Lady Gaga's Mayhem, followed ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab ... Member Prescription Program together ...

SAN FRANCISCO - OpenAI is making it easier to edit images in ChatGPT and create visuals for work that include lengthy, legible text, potentially broadening the chatbot’s appeal for businesses ...

Number 5: Patients with moderate to severe plaque psoriasis who switched between the adalimumab biosimilar GP2017 and reference adalimumab did not impact immunogenicity, safety, or efficacy following ...